---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-109335"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2021-08-25T23:59:59+00:00"
generated_at: "2026-06-29T07:54:36.271188+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Replimune eliminates CMO role; Dr. Andrea Pirzkall terminated without cause

## Summary
- All Chief Medical Officer functions now report to President and Chief R&D Officer Dr. Robert Coffin or Chief Development Operations Officer Tanya Lewis.
- Chief Medical Officer role eliminated effective August 25, 2021.
- Dr. Andrea Pirzkall notified of termination without cause on same date.

## SEC filing metadata
- accession: 0001104659-21-109335
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2021-08-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465921109335/0001104659-21-109335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465921109335/tm2125821d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-109335
- JSON: https://secwatch.observer/filing/0001104659-21-109335.json
- Plain text: https://secwatch.observer/filing/0001104659-21-109335.txt

## Key facts
- Executive change
  Dr. Andrea Pirzkall was terminated as Chief Medical Officer at Replimune Group, Inc..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: Accordingly, on August 25, 2021, the Company notified Dr. Andrea Pirzkall that her employment with the Company has terminated, without cause.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465921109335/0001104659-21-109335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.